

Introducing Dr. Alexandre Bétourné, RDCA-DAP Scientific Director



C-Path is pleased to welcome Alexandre Bétourné, PhD, PharmD, as its new Scientific Director for the Rare Disease Cures Accelerator-Data and Analytics Platform initiative. Dr. Bétourné will work with the RDCA-DAP team to expand its reach into new diseases areas accessing new data and enhancing C-Path's relationships within the rare disease community. Dr. Bétourné holds both a PhD and a PharmD from the University of Toulouse in France. He holds three patents and has written multiple papers that intersect with a number of different rare disease areas. Before joining C-Path, he led a team of senior U.S. scientists, CMC and regulatory consultants at a small company developing therapies for amyotrophic lateral sclerosis (ALS). "Alex's broad background makes him an excellent addition to the RDCA-DAP team, and we are fortunate to welcome him to C-Path," said C-Path Chief Science Officer, Klaus Romero, MD, MS, FCP.